Effect of a new de- N-acetyl-lysoglycosphingolipid on some tumour models

• Published in: European journal of pharmacology Vol. 294; no. 2; pp. 555 - 563
• Main Authors: Tubaro, Ezio, Borelli, Giorgio P., Belogi, Luisella, Cavallo, Giovanni, Santoni, Angela, Mainiero, Fabrizio
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 29.12.1995; Elsevier
• Subjects: Adhesion; Animals; Antineoplastic agents; Antineoplastic Agents - pharmacology; Biological and medical sciences; Carbohydrate Sequence; Cell Division - drug effects; Chemotherapy; Gangliosides - pharmacology; Glycosphingolipid; Humans; Male; Medical sciences; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Neoplasms, Experimental - drug therapy; Peritumoral; Pharmacology. Drug treatments; Recombinant interleukin-2; Tumor; Tumor Cells, Cultured; Tumor; Peritumoral; Glycosphingolipid; Adhesion; Recombinant interleukin-2; Drug combination; Rodentia; Malignant tumor; In vitro; Biological activity; Fibronectin; In vivo; Vertebrata; Chemotherapy; Mammalia; Laminin; Treatment; Interleukin 2; Mouse; Animal; Tumor cell
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/0014-2999(95)00583-8

A new de- N-acetylated glycosphingolipid termed WILD20, a breakdown product of GM 1 obtained through alkaline hydrolysis, and characterized by nuclear magnetic resonance, mass spectrometry and elementary analysis, was found to inhibit phospholipase A 2 via phosphokinase C translocation blockade. The substance inhibited various tumour cell lines in vitro, in synergy with doxorubicin and cisplatin. In vivo, it showed an antitumoral effect when both the tumour cells and WILD20 were injected at the same site (peritoneal cavity). Tumour cells, incubated with WILD20, showed a dose-dependent decrease of oncogenicity without impairment of viability. WILD20 also down-regulated tumour cell adherence to laminin and fibronectin. When peritumorally administered, WILD20 impaired tumour growth and potentiated the peritumoral effects of recombinant interleukin 2. The results obtained merit exploration of the therapeutical possibilities of this agent in human cancer patients.